The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.

Edits on 23 May, 2023

"Remove website redirecting to Patent Public Search front page"

Golden AI

edited on 23 May, 2023

Edits made to:

Infobox (-1 properties)

Infobox

Official Website

https://pdfpiw.uspto.gov/.piw?Docid=09161976

Edits on 21 May, 2023

"Remove leading 0 from patent number"

Golden AI

edited on 21 May, 2023

Edits made to:

Infobox (+1/-1 properties)

‌

US Patent 09161976 Immunotherapy comprising TLR9 ligand and CD40 ligand US Patent 9161976 Immunotherapy comprising TLR9 ligand and CD40 ligand

Infobox

Patent Number

09161976

Patent Number

9161976

Edits on 8 Jun, 2022

"Entity importer update"

Golden AI

edited on 8 Jun, 2022

Edits made to:

Infobox (+1 properties)

Infobox

Website URL

https://pdfpiw.uspto.gov/.piw?Docid=09161976

Edits on 3 Jan, 2022

"Created via: Entity Importer"

Golden AI

created this topic on 3 Jan, 2022

Edits made to:

Infobox (+7 properties)

‌

US Patent 09161976 Immunotherapy comprising TLR9 ligand and CD40 ligand

Infobox

Is a

Patent

Patent jurisdiction

United States Patent and Trademark Office

Patent number

09161976

Date of patent

October 20, 2015

Patent application number

13657032

Date Filed

October 22, 2012

Patent primary examiner

‌

Claire Kaufman

Find more entities like US Patent 9161976 Immunotherapy comprising TLR9 ligand and CD40 ligand

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API